{rfName}

License and Use

Icono OpenAccess

Altmetrics

Impact on the Sustainable Development Goals (SDGs)

Analysis of institutional authors

Armangue TAuthorSaiz AAuthorSepulveda MAuthorMartinez-Hernandez EAuthorOlivé-Cirera GAuthor

Share

December 26, 2022
Publications
>
Article

Significance of Myelin Oligodendrocyte Glycoprotein Antibodies in CSF: A Retrospective Multicenter Study

Publicated to: NEUROLOGY. 100 (11): e1095-e1108 - 2023-03-14 100(11), DOI: 10.1212/wnl.0000000000201662

Authors:

Carta, S; Calvo, AC; Armangué, T; Saiz, A; Lechner, C; Rostásy, K; Breu, M; Baumann, M; Höftberger, R; Ayzenberg, I; Schwake, C; Sepulveda, M; Martínez-Hernández, E; Olivé-Cirera, G; Arrambide, G; Tintoré, M; Bernard-Valnet, R; Du Pasquier, R; Brilot, F; Ramanathan, S; Schanda, K; Gajofatto, A; Ferrari, S; Sechi, E; Flanagan, EP; Pittock, SJ; Redenbaugh, V; Reindl, M; Marignier, R; Mariotto, S
[+]

Affiliations

Childrens Hosp Westmead, Kids Neuro Sci Ctr, Translat Neuroimmunol Grp SR, Westmead, Australia - Author
Concord Hosp, Dept Neurol, Sydney, Australia - Author
Department of Neurology, St. Josef-Hospital, Ruhr-University Bochum, Bochum, Germany. - Author
Division of Neuropathology and Neurochemistry, Department of Neurology, Medical University of Vienna, Vienna, Austria. - Author
Hosp Civils Lyon, Ctr Reference Malad Inflammatoires Rares Cerveau &, Sclerose Plaques Pathol Myeline & Neuroinflammat, Hopital Neurol Pierre Wertheimer,Serv Neurol, Lyon, France - Author
Hosp Clin Barcelona, Serv Neurol, Inst Invest Biomed August Pi & Sunyer IDIBAPS and, Neuroimmunol Program,Neuroimmunol & Multiple Scle, Barcelona, Spain - Author
Lausanne Univ Hosp, Dept Clin Neurosci, Serv Neurol, Lausanne, Switzerland - Author
Mayo Clin, Dept Neurol, Dept Lab Med & Pathol, Coll Med & Sci, Rochester, England - Author
Med Univ Innsbruck, Clin Dept Neurol, Innsbruck, Austria - Author
Med Univ Innsbruck, Dept Pediat & Adolescent Med, Div Pediat Neurol, Innsbruck, Austria - Author
Med Univ Vienna, Dept Neurol, Div Neuropathol & Neurochem, Vienna, Austria - Author
Med Univ Vienna, Div Pediat Pulmonol, Allergol & Endocrinol, Dept Pediat & Adolescent Med, Vienna, Austria - Author
Ruhr Univ Bochum, St Josef Hosp, Dept Neurol, Bochum, Germany - Author
Univ Autonoma Barcelona, Vall Hebron Hosp Univ, Vall Hebron Inst Recerca, Ctr Esclerosi Multiple Catalunya CEMCAT,Serv Neuro, Barcelona, Spain - Author
Univ Barcelona, Barcelona, Spain - Author
Univ Barcelona, St Joan Deu Childrens Hosp, Pediat Neuroimmunol Unit, Barcelona, Spain - Author
Univ Lausanne, Lausanne, Switzerland - Author
Univ Sassari, Dept Med Surg & Expt Sci, Sassari, Italy - Author
Univ Sydney, Kids Res Childrens Hosp Westmead, Fac Med & Hlth & Brain, Brain Autoimmun Grp, Sydney, Australia - Author
Univ Sydney, Kids Res Childrens Hosp Westmead, Mind Ctr, Kids Neurosci Ctr, Sydney, Australia - Author
Univ Verona, Dept Neurosci Biomed & Movement Sci, Neurol Unit, Verona, Italy - Author
Univ Witten, Herdecke Childrens Hosp, Div Pediat Neurol, Datteln, Germany - Author
University of Sassari, Department of Medical, Surgical and Experimental Sciences, Sassari, Italy. - Author
See more

Abstract

Although the diagnosis of myelin oligodendrocyte glycoprotein antibody associated disease (MOGAD) is based on serum MOG antibodies (MOG-Abs) positivity, patients with coexisting or restricted MOG-Abs in the CSF have been reported. The aim of this study is to characterize the relevance of CSF MOG-Abs positivity in clinical practice.Eleven medical centres retrospectively collected clinical and laboratory data of adult and pediatric patients with suspected inflammatory CNS disease and MOG-Abs positivity in serum and/or CSF, using live cell-based assays. Comparisons were performed using parametric or non-parametric tests, as appropriate. Potential factors of unfavourable outcomes were explored by Cox proportional hazard models and logistic regression.The cohort included 255 patients: 139 (55%) females and 132 (52%) children (i.e. <18 year-old). Among them, 145 patients (56.8%) had MOG-Abs in both serum and CSF (MOG-Abs seropositive and CSF positive), 79 (31%) only in serum (MOG-Abs seropositive and CSF negative), and 31 (12%) only in CSF (MOG-Abs seronegative and CSF positive). MOG-Abs seronegative and CSF positive predominated in adults (22% vs 3% of children), presented more commonly with motor (n=14, 45%) and sensory symptoms (n=13, 42%), and all but 4 (2 MS, 1 polyradiculoneuritis, 1 Susac syndrome) had a final diagnosis compatible with MOGAD. When comparing seropositive patients according to MOG-Abs CSF status, MOG-Abs seropositive and CSF positive patients had a higher EDSS at nadir during the index event (median 4.5, IQR 3.0-7.5 vs. 3.0, IQR 2.0-6.8, p=0.007) and presented more commonly with sensory (45.5% vs. 24%, p=0.002), motor (33.6% vs 19%, p=0.021), and sphincter symptoms (26.9% vs 7.8%, p=0.001) than MOG-Abs seropositive and CSF negative. At last follow-up, MOG-Abs seropositive and CSF positive cases had more often persistent sphincter dysfunction (17.3% vs 4.3%, p=0.008). Compared with seropositive patients, those MOG-Abs seronegative and CSF positive had higher disability at last follow-up (p?0.001) and MOG-Abs seronegative and CSF positive status was independently associated with an EDSS ?3.0.Paired serum and CSF MOG-Abs positivity is common in MOGAD and is associated with a more severe clinical presentation. CSF only MOG-Abs positivity can occur in patients with a phenotype suggestive of MOGAD and is associated with a worse outcome. Taken together, these data suggest a clinical interest in assessing CSF MOG-Abs in patients with a phenotype suggestive of MOGAD, regardless of the MOG-Abs serostatus.© 2022 American Academy of Neurology.
[+]

Keywords

AdolescentAdultAgedAquaporin 4ArticleAutoantibodiesCentral nervous system diseaseCerebrospinal fluidCerebrospinal fluid abnormalityChildClinical practiceCohort analysisControlled studyDiagnostic valueEncephalitisExpanded disability status scaleFemaleGood health and well-beingHumanHuman cellHumansInformation processingLive cell imagingLogistic regression analysisMajor clinical studyMaleMotor dysfunctionMultiple sclerosisMyelin oligodendrocyte glycoproteinMyelin oligodendrocyte glycoprotein antibodyMyelin-oligodendrocyte glycoproteinMyelitisNeuritisOptic neuritisPediatric patientProportional hazards modelProtein antibodyRetrospective studiesRetrospective studySensory dysfunctionSusac syndromeUnclassified drug

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal NEUROLOGY due to its progression and the good impact it has achieved in recent years, according to the agency WoS (JCR), it has become a reference in its field. In the year of publication of the work, 2023, it was in position 11/280, thus managing to position itself as a Q1 (Primer Cuartil), in the category Clinical Neurology. Notably, the journal is positioned above the 90th percentile.

From a relative perspective, and based on the normalized impact indicator calculated from World Citations provided by WoS (ESI, Clarivate), it yields a value for the citation normalization relative to the expected citation rate of: 12.06. This indicates that, compared to works in the same discipline and in the same year of publication, it ranks as a work cited above average. (source consulted: ESI Nov 13, 2025)

This information is reinforced by other indicators of the same type, which, although dynamic over time and dependent on the set of average global citations at the time of their calculation, consistently position the work at some point among the top 50% most cited in its field:

  • Weighted Average of Normalized Impact by the Scopus agency: 8.57 (source consulted: FECYT Mar 2025)

Specifically, and according to different indexing agencies, this work has accumulated citations as of 2026-04-01, the following number of citations:

  • WoS: 48
  • Scopus: 42
  • Europe PMC: 7
  • Open Alex: 40
[+]

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2026-04-01:

  • The use, from an academic perspective evidenced by the Altmetric agency indicator referring to aggregations made by the personal bibliographic manager Mendeley, gives us a total of: 46.
  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 69 (PlumX).

With a more dissemination-oriented intent and targeting more general audiences, we can observe other more global scores such as:

  • The Total Score from Altmetric: 57.
  • The number of mentions on the social network Facebook: 1 (Altmetric).
  • The number of mentions on the social network X (formerly Twitter): 68 (Altmetric).

It is essential to present evidence supporting full alignment with institutional principles and guidelines on Open Science and the Conservation and Dissemination of Intellectual Heritage. A clear example of this is:

  • The work has been submitted to a journal whose editorial policy allows open Open Access publication.
Continuing with the social impact of the work, it is important to emphasize that, due to its content, it can be assigned to the area of interest of ODS 3 - Good Health And Well-being, with a probability of 68% according to the mBERT algorithm developed by Aurora University.
[+]

Leadership analysis of institutional authors

This work has been carried out with international collaboration, specifically with researchers from: Australia; Austria; France; Germany; Italy; Switzerland; United Kingdom; United States of America.

[+]